Skip to main content
Log in

Lipoprotein abnormalities in patients with secondary renal amyloidosis

  • Published:
International Urology and Nephrology Aims and scope Submit manuscript

Abstract

The prevalance of hyperlipidemia in chronic renal failure (CRF) patients is higher than in general population. Secondary amyloidosis is a common cause of CRF in Turkey. In this study, 25 patients with CRF due to secondary renal amyloidosis (amyloid-CRF), 15 patients with CRF without amyloidosis-CRF and 17 healthy controls were studied for serum lipid parameters. The mean serum lipoprotein (a) [LP(a)] level in the patients with amyloid-CRF was significantly higher than in the controls (p < 0.01). The mean serum apolipoprotein B (Apo B), apolipoprotein E (Apo E) and triglyceride levels in the patients with amyloid-CRF were very significantly higher than in the controls (p < 0.001). The mean serum total cholesterol, low- density lipoprotein (LDL) levels in the patients with amyloid-CRF were higher than in the controls (p < 0.05). The mean serum apo AI levels in the patients with amyloid-CRF was very significantly lower than in the controls (p < 0.001).The mean serum high-density lipoprotein (HDL) in the patients with amyloid-CRF was lower than in the controls (p < 0.05). The mean serum Lp (a), Apo AI, Apo B and Apo E levels in the patients with amyloid-CRF were significantly higher than in the patients with CRF (p < 0.01). The mean serum total cholesterol, trigliserides, LDL and HDL levels in the patients with amyloid-CRF were higher than in the patients with CRF (p < 0.05).There was not any correlation with serum lipid parameters and serum albumin and urine protein levels (p < 0.05).Our study suggests that serum lipid parameters are abnormal and might be the risk factor of atherosclerotic vascular disease and contribute to renal disease progression in the patients with secondary renal amyloidosis and lipid abnormalities were different from CRF with various etiology, without amyloidosis.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Kasiske LB. Hyperlipidemia in patients with chronic renal disease. Am J Kidney Dis 1998; 5(suppl 3): 142–156.

    Google Scholar 

  2. Samuelsson O, Mulec H, Knight-Gibson C, Attman P-O, Kron B, Larsson R, Weiss L, Wedel H, Alaupovic P. Lipoprotein abnormalities are associated with increased rate of progression of human chronic renal insufficiency. Nephrol Dial Transplant 1997; 12: 1908–1915.

    Article  PubMed  CAS  Google Scholar 

  3. Nichols WC, Dwulet FE, Liepnieks J, Benson MD. Variant lipoprotein AI as a major constituent of a human hereditary amyloid Biochem Biophys Res Commun 1988; 156: 762–768.

    Article  PubMed  CAS  Google Scholar 

  4. Nichols WC, Gregg RE, Brewer HB, Benson MD. A mutation in apolipoprotein AI in lowa type of familial amyloidotic polyneuropaty, Genomics 1990; 8: 318–323.

    Article  PubMed  CAS  Google Scholar 

  5. Benson MD. Apolipoprotein AI and amyloidosis: A genetic model for aging, Kidney Int 1998; 53: 508–509.

    Article  PubMed  CAS  Google Scholar 

  6. Dergunov AD, Varotnikova YY. The interaction of human serum albumin in the native and fully reduced states with apolipoprotein E, serum amyloid protein and very low denisty lipoporteins from human plasma. International Journal of Biochemistry 1994; 26(7): 933–942.

    Article  PubMed  CAS  Google Scholar 

  7. Persey MR, Booth DR, Booth SE, Van Zyl-Smit R, Adams BK, Fattar AB, Tennent GA, Hawkins PN, Pepys MB. Hereditary Nephropathic systemic amyloidosis caused by a novel variant apolipoprotein AI. Kidney Int 1998; 53: 276–281.

    Article  PubMed  CAS  Google Scholar 

  8. Friedewold WT, Levy RI, Fredrickson DS. Estimation of the concentration of Low-density lipoproteins cholesterol in plasma, without use of preparative ultracentrifuge. Clin Chem 1972; 18: 499–502.

    Google Scholar 

  9. Booth DR, Tan SY, Booth SE, Hsuan JJ, Totty NF, Nguygen O, Hutton T, Vigushin DM, Tennet GA, Hutchinson WL, Thomson N, Soutar AK, Hawkins PN, Pepys MB. A new apolipoprotein AI variant, Trp50 Arg, causes hereditary amyloidosis. Q J Med 1995; 88: 695–702.

    CAS  Google Scholar 

  10. Hanes D, Zech L, Murrell JR, Benson MD. Metabolism of normal and Met 30 transthyretin, in Advenced in foot and nutrition research (Chapter 8, metabolism of transthyretin 1996; 40: 149–155.

    CAS  Google Scholar 

  11. Elisaf M, Katopodis K, Siamopoulos KC. Lp(a) Concentration and serum albumin in hemodialysis patients. Nephrol Dial Transplant 1996; 11(5): 908–909.

    PubMed  CAS  Google Scholar 

  12. Siamopoulos KC, Elisaf M, Bairaktari E, Pappas M, Sferopoulos G, Nikolakakis N, Lipid Parameters including Lp(a) in Patients Undergoing continuous ambulatory peritoneal dialysis and hemodialysis. Perit Dial Int 1995; 15(8): 342–347.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Rights and permissions

Reprints and permissions

About this article

Cite this article

Cengiz, K., Bakan, A. & Yılmaz, H. Lipoprotein abnormalities in patients with secondary renal amyloidosis. Int Urol Nephrol 32, 615–619 (2001). https://doi.org/10.1023/A:1014476407047

Download citation

  • Issue Date:

  • DOI: https://doi.org/10.1023/A:1014476407047

Navigation